ArticleFrontiers in immunology2026
Cisplatin - induced peripheral neuropathy and biomarkers of gut microbial translocation in testicular germ cell tumor survivors.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin-induced peripheral neuropathy (CIPN) is a frequent and often persistent complication in survivors of testicular germ cell tumors (GCT) treated with curative therapy. Although several mechanisms have been proposed, the biological drivers of long-term neurotoxicity remain incompletely understood. Disruption of intestinal barrier integrity during chemotherapy or radiotherapy may promote gut microbial translocation (GMT), leading to systemic immune activation and chronic inflammation that could contribute to neuropathy development. This study investigated the relationship between circulating biomarkers of GMT and symptoms of CIPN in long-term GCT survivors. Methods: A total of 170 GCT survivors (median age 41 years) from the National Cancer Institute of Slovakia were included, with a median follow-up of 10 years after treatment. Participants completed the EORTC QLQ-CIPN20 questionnaire assessing sensory, motor, and autonomic neuropathy. Peripheral blood samples were analyzed for plasma biomarkers associated with gut microbial translocation and innate immune activation, including soluble CD14 (sCD14), high-mobility group box-1 (HMGB1), lipopolysaccharide (LPS), and D-lactate. Associations between biomarker concentrations and CIPN scores were evaluated across treatment groups: orchiectomy only (active surveillance, n=28), cisplatin-based chemotherapy (n=119), radiotherapy (n=14), and combined chemoradiotherapy (n=9). Results: Patients with higher plasma sCD14 levels had significantly higher overall CIPN scores (7.6% increase, p=0.019) and worse sensory function (9.5% increase, p=0.019) compared with those with lower levels. Patients treated with chemotherapy exhibited significantly higher plasma sCD14 levels than those under active surveillance (6613 vs. 3768 μg/L, p = 0.009). Among chemotherapy-treated patients, elevated sCD14 was associated with a higher risk of motor neuropathy (RR = 3.5, 95% CI 1.21-10.14, p=0.020). In survivors receiving combined chemotherapy and radiotherapy, increased sCD14 levels were associated with a higher risk of autonomic neuropathy (RR = 2.85, 95% CI 1.11-7.30, p=0.029). Elevated HMGB1 was also associated with an increased probability of autonomic dysfunction (RR = 2.15, 95% CI 1.07-4.33, p=0.015). No significant associations were observed between cumulative cisplatin dose and GMT biomarkers. Conclusion: Elevated biomarkers of gut microbial translocation, particularly sCD14, are associated with increased severity of CIPN in long-term GCT survivors. These findings support the hypothesis that treatment-related intestinal barrier disruption and subsequent immune activation may contribute to persistent neurotoxicity in cancer survivorship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.